Finally, we examined the endogenous expression of miR29b and its target DNMT3B in freshly purified plasma cells (CD138+) from bone marrow of 20 MGUS and 25 MM patients relative to control patients with benign hematological diseases. This evidence concerns the gene DNMT3B and hematologic disorder.